Release Date: March 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: What caused the restatement of RX revenues in the annual report? A: Daniel Wuest, CFO, clarified that there was no specific restatement for RX revenues. A restatement of CHF 3 million was due to a positive legal decision, resulting in a cashback from suppliers, but it was not specific to RX revenues.
Q: Can you confirm the 50% RX growth for Q1 2025? A: Walter Hess, CEO, confirmed that the 50% growth is based on the EUR 37 million base from Q1 last year, reflecting growth in both euros and local currency.
Q: How will the introduction of the electronic patient record in Germany affect customer journeys? A: Walter Hess, CEO, stated that the electronic patient record will be beneficial, enhancing the ecosystem approach and improving customer convenience. Although the nationwide rollout may take time, it is seen as a positive development.
Q: What is the current status of discussions with potential investors for the CHF 200 million capital raise? A: Daniel Wuest, CFO, expressed confidence in raising the CHF 200 million through a rights issue, supported by positive feedback from mandated banks. Selling a stake in Teleclinic is considered a last resort.
Q: Why is there no guidance beyond Q1 2025? A: Daniel Wuest, CFO, explained that due to the ongoing capital raise and related legal restrictions, detailed guidance will be provided closer to the capital increase, ensuring alignment with offering documents.
Q: How does the company plan to manage marketing expenditures with the capital increase? A: Daniel Wuest, CFO, indicated that while the capital increase will allow for targeted marketing investments, the funds will be used judiciously, with a focus on safeguarding the convertible bond and supporting growth.
Q: Can you explain the discrepancy between the average order value (AOV) figures for ERX and the basket sizes shown in the KPIs? A: Walter Hess, CEO, clarified that the CHF 110 AOV includes mixed baskets of RX and OTC products, while the CHF 98 figure is purely for RX, reflecting a mix of new and existing customers.
Q: What is the impact of the ECJ ruling on bonuses and incentives? A: Walter Hess, CEO, noted that the ECJ ruling reaffirmed the 2016 decision on direct bonuses, which is positive. The case now returns to the German court for OTC-related bonuses. Long-term, convenience is expected to outweigh bonuses as a customer driver.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.